AtheroNova, operating through its wholly owned subsidiary AtheroNova Operations, is focused on the discovery, research, development, and licensing of novel compounds designed to reduce or eliminate atherosclerotic plague deposits in humans. In addition to its lead compound, AHRO-001, AHRO expects to develop multiple applications for its patents-pending therapies to address cardiovascular disease, stroke, peripheral artery disease, dementia and Alzheimer’s, and erectile dysfunction, all of which have been linked to atherosclerosis.  For more information, visit the company’s Web site at:  www.atheronova.com

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its ninth annual equity conference at The Hard Rock Hotel in Ft. Lauderdale, FL. Attended by institutional investors from across North America, the event features 135 public company executive teams with an emphasis on healthcare, technology, defense, and new-media / entertainment sectors.

Let us hear your thoughts below: